HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

[Kawasaki disease].

Abstract
First described in Japan in 1967, Kawasaki disease is now observed in all countries. Despite extensive research, the aetiology of this infectious disease which affects mainly infants and young children remains mysterious. The six main clinical presentations of Kawasaki disease are: prolonged fever, conjunctivitis, lesions of the oral and pharyngeal mucosa, inflammatory reddening and swelling of the hands and feet, skin rash and cervical lymph node enlargement. Laboratory data show an inflammatory syndrome and thrombocytosis. The disease usually resolves within a few weeks. The major risk is cardiovascular involvement with pericarditis, myocarditis and, chiefly, coronary artery aneurysms which usually regress but are the main cause of mortality (1 to 2 p. 100 of the cases). Treatment consists of gammaglobulins and aspirin in high doses; when administered at an early stage, it prevents the formation of coronary aneurysms.
AuthorsD Floret
JournalLa Revue du praticien (Rev Prat) Vol. 40 Issue 28 Pg. 2604-8 (Dec 01 1990) ISSN: 0035-2640 [Print] France
Vernacular TitleLa maladie de Kawasaki.
PMID1704148 (Publication Type: English Abstract, Journal Article, Review)
Chemical References
  • gamma-Globulins
  • Aspirin
Topics
  • Aspirin (therapeutic use)
  • Child
  • Humans
  • Mucocutaneous Lymph Node Syndrome (diagnosis, drug therapy, etiology)
  • gamma-Globulins (therapeutic use)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: